UK markets close in 7 hours 35 minutes
  • FTSE 100

    7,119.51
    -4.35 (-0.06%)
     
  • FTSE 250

    23,353.67
    +5.94 (+0.03%)
     
  • AIM

    1,257.53
    -1.35 (-0.11%)
     
  • GBP/EUR

    1.1748
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.3920
    +0.0035 (+0.25%)
     
  • BTC-GBP

    27,867.00
    +589.62 (+2.16%)
     
  • CMC Crypto 200

    959.75
    +32.98 (+3.56%)
     
  • S&P 500

    4,402.66
    -20.49 (-0.46%)
     
  • DOW

    34,792.67
    -323.73 (-0.92%)
     
  • CRUDE OIL

    68.05
    -0.10 (-0.15%)
     
  • GOLD FUTURES

    1,814.80
    +0.30 (+0.02%)
     
  • NIKKEI 225

    27,728.12
    +144.04 (+0.52%)
     
  • HANG SENG

    26,200.39
    -226.16 (-0.86%)
     
  • DAX

    15,711.19
    +19.06 (+0.12%)
     
  • CAC 40

    6,770.41
    +24.18 (+0.36%)
     

Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021.

Details for the fireside chat are below:

Jefferies Virtual Healthcare Conference
Date: Wednesday, June 2, 2021
Time: 1:30 PM ET

A live webcast of the fireside chat will be accessible on the Company’s website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005350/en/

Contacts

Investor Contact:
Alex Kelly
Interim Chief Financial Officer
Alex.Kelly@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting